Introduction and Objective: This post hoc analysis assessed the efficacy and hypoglycemia outcomes with once-weekly insulin icodec (icodec) vs once-daily (OD) basal insulin comparators in insulin-naive (ONWARDS 1, 3, 5) and insulin-experienced (ONWARDS 2, 4) adults with T2D by baseline A1C.Methods: Treatment outcomes were analyzed, by trial, across baseline A1C subgroups (≤8%, >8-≤9%, >9%).Results: Overall, a numerically greater reduction in A1C was seen with icodec vs OD comparators across A1C subgroups in all trials, except for the >8-≤9% and >9% subgroups in ONWARDS 4 (basal-bolus trial) (Figure). There was no statistically significant treatment by A1C subgroup interaction in any trial for change in A1C from baseline to planned end of treatment (EOT). Rates of clinically significant or severe hypoglycemia were low (<1 event/patient-year of exposure) across arms irrespective of baseline A1C except in ONWARDS 4 where rates were numerically higher in both arms across subgroups. There was no statistically significant treatment by A1C subgroup interaction in any trial for the achievement of A1C <7% at EOT without clinically significant or severe hypoglycemia in the prior 12 weeks.Conclusion: Efficacy and hypoglycemia outcomes for icodec vs OD comparators were overall similar across baseline A1C subgroups.
C. Mathieu: Advisory Panel; Novo Nordisk, Sanofi, Eli Lilly and Company, Abbott, Medtronic, SAB Biotherapeutics, Inc, Roche Diabetes Care, Vertex Pharmaceuticals Incorporated, Biomea Fusion, Bayer Pharmaceuticals, Inc. L.S. Canani: Advisory Panel; Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Research Support; Lilly Diabetes, Amgen Inc. J.K. Lindeløv: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S, Lundbeck. S.B. Søgaard: Employee; Novo Nordisk. S.M. Vinther: Employee; Novo Nordisk. A.Y. Cheng: Advisory Panel; Abbott. Speaker’s Bureau; Abbott. Other Relationship; American Diabetes Association. Speaker’s Bureau; Amgen Inc, AstraZeneca. Advisory Panel; Bayer Pharmaceuticals, Inc. Speaker’s Bureau; Bayer Pharmaceuticals, Inc. Advisory Panel; Boehringer-Ingelheim. Speaker’s Bureau; Boehringer-Ingelheim. Advisory Panel; Dexcom, Inc., Eisai, Eli Lilly and Company. Speaker’s Bureau; Eli Lilly and Company, GlaxoSmithKline plc. Advisory Panel; Insulet Corporation. Speaker’s Bureau; Insulet Corporation. Advisory Panel; HLS Therapeutics. Speaker’s Bureau; HLS Therapeutics, Medtronic. Advisory Panel; Novo Nordisk. Speaker’s Bureau; Novo Nordisk, Pfizer Inc. Advisory Panel; Sanofi. Speaker’s Bureau; Sanofi. Consultant; Novo Nordisk, Applied Therapeutics, Vertex Pharmaceuticals Incorporated.
Novo Nordisk A/S
Source link
Leave a Reply